Get the Stockscreener App
17.49
6.26%
1.04
Pacira Biosciences Inc stock is traded at $17.49, with a volume of 222.64K.
It is up +6.26% in the last 24 hours and up +5.84% over the past month.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
See More
Previous Close:
$16.45
Open:
$16.31
24h Volume:
222.64K
Relative Volume:
0.21
Market Cap:
$783.80M
Revenue:
$681.75M
Net Income/Loss:
$70.47M
P/E Ratio:
194.33
EPS:
0.09
Net Cash Flow:
$173.19M
1W Performance:
+1.74%
1M Performance:
+5.84%
6M Performance:
-35.76%
1Y Performance:
-43.69%
1-Day Range:
$16.24
$17.53
1-Week Range:
$16.09
$17.53
52-Week Range:
$11.16
$35.95
Pacira Biosciences Inc Stock (PCRX) Company Profile
Name
Pacira Biosciences Inc
Sector
Phone
813-553-6680
Address
5401 WEST KENNEDY BOULEVARD, TAMPA, NJ
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-23 | Initiated | Raymond James | Outperform |
| Aug-03-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Jan-31-23 | Resumed | Wedbush | Outperform |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Jan-03-22 | Resumed | JP Morgan | Overweight |
| Jul-26-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-21-21 | Resumed | JP Morgan | Neutral |
| Apr-09-21 | Initiated | Berenberg | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-11-21 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jan-21-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jul-06-20 | Reiterated | Needham | Buy |
| May-27-20 | Initiated | Guggenheim | Neutral |
| Apr-07-20 | Initiated | Northland Capital | Outperform |
| Mar-20-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-24-20 | Initiated | SunTrust | Buy |
| Jan-23-20 | Initiated | SunTrust | Buy |
| Nov-06-19 | Initiated | BTIG Research | Buy |
| Jun-11-19 | Initiated | Barclays | Overweight |
| May-06-19 | Upgrade | Mizuho | Underperform → Neutral |
| May-02-19 | Upgrade | Stifel | Sell → Hold |
| Feb-01-19 | Downgrade | Mizuho | Neutral → Underperform |
| Aug-06-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Apr-09-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-21-18 | Reiterated | Mizuho | Neutral |
| Feb-16-18 | Downgrade | Needham | Buy → Hold |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
| Jan-04-18 | Reiterated | Canaccord Genuity | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Mkt Perform |
View All
Pacira Biosciences Inc Stock (PCRX) Latest News
Pacira BioSciences Inc (PCRX) Q3 2024: Everything You Need To Kn - GuruFocus.com
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Trading (PCRX) With Integrated Risk Controls - Stock Traders Daily
Rice Hall James & Associates LLC Sells 730,288 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Pacira BioSciences (PCRX) Set to Announce Quarterly Earnings on Wednesday - MarketBeat
Allspring Global Investments Holdings LLC Buys 93,497 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024 - GlobeNewswire
Assenagon Asset Management S.A. Buys 419,656 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Shawn Cross appointed as chief financial officer for Pacira Biosciences - Pharmafile
When the Price of (PCRX) Talks, People Listen - Stock Traders Daily
Pacira BioSciences appoints Shawn Cross as CFO By Investing.com - Investing.com Australia
Pacira BioSciences appoints Shawn Cross as CFO - Investing.com
Are Options Traders Betting on a Big Move in Pacira BioSciences (PCRX) Stock? - MSN
Pacira BioSciences Appoints Shawn Cross As Chief Financial Officer - citybiz
Pacira BioSciences Names Shawn Cross Chief Financial Officer - MarketWatch
Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer - GlobeNewswire
Q1 EPS Estimate for Pacira BioSciences Reduced by Analyst - MarketBeat
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Purchased by Wedge Capital Management L L P NC - MarketBeat
Pacira BioSciences Inc (PCRX) may enjoy gains as insiders got busy in the recent days - Knox Daily
Was Pacira BioSciences Inc (PCRX)’s session last reading good? - US Post News
(PCRX) Trading Advice - Stock Traders Daily
A company insider recently sold 500 shares of Pacira BioSciences Inc [PCRX]. Should You Sale? - Knox Daily
What is the investor’s view on Pacira BioSciences Inc (PCRX)? - US Post News
Analysts Set Pacira BioSciences, Inc. (NASDAQ:PCRX) PT at $24.20 - MarketBeat
Analytical Overview: Pacira BioSciences Inc (PCRX)’s Ratios Tell a Financial Story - The Dwinnex
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by Bank of Montreal Can - MarketBeat
PCRX stock rated a Sell by Truist - Knox Daily
A Look at Pacira BioSciences Inc (PCRX) Shares in the Recent Past Indicates Growth - SETE News
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Sei Investments Co. Sells 279,140 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Are Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Mixed Financials Driving The Negative Sentiment? - Simply Wall St
The three-year loss for Pacira BioSciences (NASDAQ:PCRX) shareholders likely driven by its shrinking earnings - Yahoo Finance
Pacira BioSciences (NASDAQ:PCRX) Price Target Raised to $15.00 at Royal Bank of Canada - MarketBeat
Pacira's Exparel Receives Permanent New Product-Specific J-Code - Zacks Investment Research
Pacira wins Exparel Medicare J-code (NASDAQ:PCRX) - Seeking Alpha
Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025 - GlobeNewswire
CMS grants new J-code for Pacira's non-opioid pain therapy - Investing.com
Pacira BioSciences Inc (PCRX)’s stock rises to 15.30 per share - US Post News
Pacira BioSciences' SWOT analysis: stock faces patent challenges amid growth initiatives - Investing.com India
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Acquired by Dimensional Fund Advisors LP - MarketBeat
Pacira Pharmaceuticals Announces CFO Transition and Interim Replacement - TipRanks
Marshall Wace LLP Acquires 159,791 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Pacira to present new gene therapy data for knee osteoarthritis By Investing.com - Investing.com Australia
Doma Perpetual Capital Management LLC Has $28.63 Million Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Pacira Announces the Presentation of 104-Week Safety and - GlobeNewswire
Pacira to present new gene therapy data for knee osteoarthritis - Investing.com
Pacira BioSciences (NASDAQ:PCRX) Shares Gap Up After Analyst Upgrade - MarketBeat
DOMA Perpetual Sends Letter to Board of Directors of Pacira Biosciences to Immediately Accelerate and Increase its Share Buyback Program to Enhance Return to Shareholders - PR Newswire
Pacira BioSciences (NASDAQ:PCRX) Price Target Increased to $18.00 by Analysts at Jefferies Financial Group - MarketBeat
Expert Ratings For Pacira BioSciences - Benzinga
Pacer Advisors Inc. Purchases 590,082 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Pacira Biosciences Inc Stock (PCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.16%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):